Abstract:Abstract The incidence and prevalence of non‐alcoholic fatty liver disease (NAFLD) have been steadily increasing worldwide, with a huge societal and economic burden. Recently, NAFLD and non‐alcoholic steatohepatitis have been renamed and redefined as metabolic dysfunction associated steatotic liver disease (MASLD) and steatohepatitis (Metabolic Dysfunction Associated Steatohepatitis (MASH)), which result from an imbalance between metabolic and inflammatory stress (mainly as a consequence of adipose tissue dysfunction and insulin resistance) and the defence and repair mechanisms of the steatotic liver. Once MASLD progresses to end‐stage of liver disease, treatment efficacy becomes limited and may require liver transplantation. Early detection and intervention are crucial. Lifestyle modification is consequently the cornerstone of its management. Timely consideration of bariatric surgeries should be given to patients meeting specific criteria. A multidisciplinary approach is warranted, starting from the concept that MASLD/MASH is at the centre of the cardiovascular‐liver‐metabolic syndrome. In some cases, pharmacological treatment can complement lifestyle modification. Several drugs used to treat the cardiometabolic co‐morbidities have some potential efficacy in slowing Down disease progression, and some have demonstrated efficacy on histological endpoints that are likely to translate into long‐term clinical benefits. Optimising the use of these drugs within their licenced indications is thus paramount for patients with MASLD. Several MASH‐specific drugs are on the horizon and are likely to enrich our therapeutic armamentarium in the near future, particularly in non‐cirrhotic stages of the disease. Much work still needs to be done to understand the specific features of MASH cirrhosis and develop efficacious treatments for this disease stage.

Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease

Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies

Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges

Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism

Metabolic-associated steatotic liver disease and hepatocellular carcinoma

Updated mechanisms of MASLD pathogenesis

A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis

Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC

Current Progress and Challenges in the Development of Pharmacotherapy for Metabolic Dysfunction‐Associated Steatohepatitis

Therapeutic management of metabolic dysfunction associated steatotic liver disease

Epidemiology, Screening, and Co-management of Type 2 Diabetes Mellitus and Metabolic-dysfunction Associated Steatotic Liver Disease

MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options

Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic

The double roles of T cell-mediated immune response in the progression of MASLD

Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

The Mechanism and Therapeutic Prospect of Autophagy in Metabolic Dysfunction-Associated Steatotic Liver Diseas

Targeting ketone body metabolism to treat fatty liver disease